Journal
CURRENT ALLERGY AND ASTHMA REPORTS
Volume 8, Issue 1, Pages 37-44Publisher
CURRENT SCIENCE INC
DOI: 10.1007/s11882-008-0008-8
Keywords
-
Categories
Ask authors/readers for more resources
Both beta-blockers and allergen immunotherapy are frequently prescribed, and allergy/immunology physicians commonly encounter patients who are candidates for immunotherapy and are receiving beta-blockers. The evidence in the medical literature indicates that although anaphylaxis does not appear to be more frequent, beta-blocker exposure is associated with greater risk for severe anaphylaxis, and for anaphylaxis refractory to treatment. Use of beta-blocker suspension merits consideration to reduce risk for untoward outcomes, while supplanting the beta-blocker medication with an equally efficacious non-beta-blocker alternative. For patients who require a beta-blocker for an indication for which there is no equally effective substitute, a management decision by the physician prescribing allergen immunotherapy should be approached carefully from an individualized risk-benefit standpoint.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available